MBTPS1 and cancer: Furthermore, the feasibility and safety of this approach is supported by previous phase I and phase II clinical trials using LX2931/LX3305 for the treatment of rheumatoid arthritis (NCT01417052 and NCT00903383); thus, opening the way for the repurposing of this drug or development of other S1P modulators as tumor vascular normalizing therapies for cancer patients.